The global cell therapy market size was exhibited at USD 4.85 billion in 2023 and is projected to hit around USD 37.42 billion by 2033, growing at a CAGR of 22.67% during the forecast period 2024 to 2033.
.webp "Cell Therapy Market Size, 2024 to 2033")
Key Takeaways:
Cell Therapy Market Report Scope
| Report Coverage | Details |
| Market Size in 2024 | USD 5.95 Billion |
| Market Size by 2033 | USD 37.42 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 22.67% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Therapy Type, Therapeutic Area, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Novartis AG; Gilead Sciences, Inc.; Bristol-Myers Squibb Company; Johnson & Johnson Services, Inc; JCR Pharmaceuticals Co., Ltd.; JW Therapeutics; Atara Biotherapeutics; Anterogen Co., Ltd.; MEDIPOST; S. BIOMEDICS |
The market for cell therapy is constantly growing to include new cell types, which presents significant opportunities for companies to strengthen their market positions. As a result, during the past few years, there has been a dramatic increase in the number of companies engaged in developing cell therapies.
The rise in funding for cell therapy clinical studies, the adoption of useful guidelines for cell therapy manufacturing, and the success of products are some of the major factors influencing the growth in the number of companies in the market. The development of cell banking facilities and the ensuing growth in cell manufacturing, storage, and characterization have enhanced the market's ability to handle large volumes on a global scale. Furthermore, several companies are offering cell therapy characterization research and analysis services which is boosting the growth of cell-based therapeutics manufacturing. This has directly contributed to the market's increased revenue generation over the previous few years.
The increase in the number of clinical trials can be attributed to the presence of private and government funding agencies that are constantly providing approvals to support projects across different stages of clinical trials. The majority of late-stage projects in Europe are receiving funds through EU grants. For instance, in July 2023, Achilles Therapeutics declared that it had been awarded a USD 4.2 million Horizon Europe, the EU’s key funding initiative for research and innovation. This funding was awarded to advance personalized therapy manufacturing.
The rise of personalized medicine has led to an increase in clinical studies. Cellular therapies, especially those involving genetically modified cells, offer the potential for customized treatments that target the unique genetic makeup of individual patients. This personalized analysis enhances treatment effectiveness and minimizes adverse effects, marking a paradigm shift in the way healthcare is delivered.
Stem cell therapy is also increasingly gaining attention due to its applications in therapeutics for autoimmune and metabolic disorders. It plays an essential role in developing immunity in an individual to fight against various metabolic disorders. For instance, in May 2023, Sernova and Evotec entered into a collaboration for development of cell therapy to be used for the treatment of insulin-dependent diabetes using induced pluripotent stem cells (iPSC)-based therapeutics.
In addition, automation in adult stem cells & cord blood processing and storage are the key technologies expected to positively influence growth of the adult & cord blood cells market. Furthermore, key entities in the market are involved in collaborations to reprogram newborn stem cells from umbilical cord blood as well as tissue into induced pluripotent stem cells (IPSCs). These developments are expected to drive growth of market over the forecast period.
Market Concentration & Characteristics
The cell therapy landscape is also characterized by a high degree of innovation. Pioneering research and technological breakthroughs are enhancing the efficacy and safety of cell-based therapies. These innovations encompass several key areas, from novel cell sources and manufacturing techniques to optimized delivery methods.
Companies are pursuing mergers and acquisition strategies to strengthen their pipelines, expand geographical reach, and accelerate product development. As the cell therapy industry matures, M&A activities serve as a pivotal force in consolidating resources, optimizing manufacturing capabilities, and securing intellectual property, fostering a competitive landscape for sustainable growth.
The increasing availability of advanced cell engineering technologies and genetic editing tools, such as CRISPR-Cas9, has led to an increased focus on regulations in this industry. Regulatory measures for enhancing efficacy & reducing the risk of adverse reactions are expected to present significant challenges for market growth.
The market is also witnessing high levels of product and regional expansion due to rising number of approvals for cell-based therapeutics granted by key regulatory authorities such as the U.S. FDA and EMA in recent years. This attribute is anticipated to fuel market growth in near future.
Segments Insights:
Therapy Type Insights
Autologous therapy segment dominated the market with a share of 92.0% in the year 2023. The growth in the segment is attributed to the high adoption of numerous CAR-T therapies owing to its favorable outcomes for treatment of various types of cancers and genetic disorders. The FDA has approved some of such therapies and their wider adoption is currently under progress. For instance, in February 2023, the U.S. FDA accorded its approval to the drug called ciltacabtagene autoleucel (Carvykti) for adult subjects with multiple myeloma that is irresponsive to the refractory therapeutics or that has relapsed after therapeutics.
.webp "Cell Therapy Market Share, By Therapy Type, 2023 (%)")
Allogeneic cell therapy segment is estimated to register substantial growth in the market from 2024 to 2030. The growth can be attributed to its high adoption for designing novel therapeutic regimes. There are 542 active allogenic CAR-T agents in the global pipeline, with many of them yielding favorable outcomes. For instance, Adaptimmune Ltd. collaborates with Genentech to focus on utility of allogeneic therapies derived from iPSCs to create T-cells with higher proliferation capacity than the mature T-cells.
Therapeutic Area Insights
The oncology segment dominated the overall market with the largest revenue share 78% in 2023. CAR T-cells targeting CD19 are reported to provide high rates of complete and long-lasting remissions for patients with acute lymphocytic leukemia (ALL). Furthermore, increasing FDA approval for novel therapies is expected to create growth opportunities for the market. For instance, in October 2021, the U.S. FDA approved the use of the brexucabtagene autoleucel (Tecartus), a CAR T therapy for individuals with B-cell precursor ALL who have not responded to prior treatment (refractory) or whose condition has returned after treatment. With this approval, brexucabtagene became the first CAR T treatment for adults with ALL.
The musculoskeletal disorders segment is anticipated to witness significant market expansion in the forthcoming years. Considerable research is being conducted on technologies aimed at enabling the regeneration or restoration of impaired musculoskeletal tissues. Researchers across diverse groups are analyzing clinically applicable cell types used in therapies to address musculoskeletal tissue degeneration. They are also exploring the direct application of engineered or native skeletal progenitor cells to stimulate tissue repair and revitalize musculoskeletal tissues. These factors are expected to drive the segment growth.
Regional Insights
North America accounted for the largest revenue share of 60.0% in 2023. This is attributed to the collaborative research initiatives by research institutes and the pharmaceutical giants. There are emerging advancements in the region through numerous collaborations. For instance, in June 2023, Immatics entered into a collaboration with Bristol Myers Squibb to develop Gamma Delta Allogeneic Cell Therapy Programs. The availability of funds from government organizations significantly contributes to market growth in the U.S. For instance, in January 2023, Cellino Biotech announced that it raised around USD 80 million through a Series A financing round from 8VC, Felicis Ventures, and other investors. The company plans to use these funds to expand access to stem cell-derived therapies to develop the first independent human cell foundry by 2025.
Asia Pacific is estimated to register a significant CAGR during the forecast period due to increased demand for cell therapy in the region. Certain factors, such as increasing awareness about novel therapies, growing investments, and expected favorable policies by governments, are estimated to accelerate market growth during the forecast period. For instance, in June 2023, Tessa Therapeutics Ltd. raised USD 126 million through rounds of series funding to catalyze the development of next-generation cancer therapy. Similarly, the South Korean market is expected to exhibit lucrative growth due to various strategic initiatives undertaken by local players and international companies. For instance, in August 2023, Panacell Biotech announced that it would be using Natural Killer (NK) cells, brown Adipose-Derived Stem Cells (ADSC), and exosomes for treating COVID-19 infection.
Recent Developments
Some of the prominent players in the Cell therapy market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global cell therapy market.
Therapy Type
Therapeutic Area
By Region
Chapter 1. Cell Therapy Market: Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Therapy Type Segment
1.1.2. Therapeutic Area Segment
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List Of Secondary Sources
1.8. List Of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Cell Therapy Market: Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Landscape Insights
Chapter 3 Cell Therapy Market: Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rise In The Number Of Clinical Studies Pertaining To The Development Of Cellular Therapies
3.2.1.2 Rising Adoption Of Regenerative Medicine
3.2.1.3 Introduction Of Novel Platforms And Technologies
3.2.2 Market Restraint Analysis
3.2.2.1 Ethical Concerns Related To Stem Cell Research
3.2.2.2 Clinical Issues Pertaining To Development & Implementation Of Cell Therapy
3.3 Industry Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 PESTEL Analysis
3.3.3 COVID-19 Impact Analysis
Chapter 4 Cell Therapy Market Categorization: Therapy Type Estimates & Trend Analysis
4.1 Allogeneic Cell Therapy
4.1.1 Global Allogeneic Cell Therapy Market, 2021 - 2033
4.1.2 Stem Cell Therapies
4.1.2.1 Global Allogeneic Cell Therapy Market For Stem Cell Therapies, 2021 - 2033
4.1.2.2 Hematopoeitic Stem Cell Therapies
4.1.2.2.1 Global Allogeneic Cell Therapy Market For Hematopoeitic Stem Cell Therapies, 2021 - 2033
4.1.2.3 Mesenchymal Stem Cell Therapies
4.1.2.3.1 Global Allogeneic Cell Therapy Market For Mesenchymal Stem Cell Therapies, 2021 - 2033
4.1.3 Non-Stem Cell Therapies
4.1.3.1 Global Allogeneic Cell Therapy Market For Non-Stem Cell Therapies, 2021 - 2033
4.1.3.2 Keratinocytes & Fibroblast-Based Therapies
4.1.3.2.1 Global Allogeneic Cell Therapy Market For Keratinocytes & Fibroblast-Based Therapies, 2021 - 2033
4.1.3.3 Others
4.1.3.3.1 Global Allogeneic Cell Therapy Market For Other Non-Stem Cell Therapies, 2021 - 2033
4.2 Autologous Cell Therapy
4.2.1 Global Autologous Cell Therapy Market, 2021 - 2033
4.2.2 Stem Cell Therapy
4.2.2.1 Global Autologous Cell Therapy Market For Stem Cell Therapy, 2021 - 2033
4.2.2.2 BM, Blood, & Umbilical Cord-Derived Stem Cells
4.1.2.2.1 Global Autologous Cell Therapy Market For BM, Blood, & Umbilical Cord-Derived Stem Cells, 2021 - 2033
4.2.2.3 Adipose Derived Cells
4.1.2.3.1 Global Autologous Cell Therapy Market For Adipose Derived Cells, 2021 - 2033
4.2.2.4 Others
4.2.2.4.1 Global Autologous Cell Therapy Market For Other Therapies, 2021 - 2033
4.2.3 Non-Stem Cell Therapy
4.2.3.1 Global Autologous Cell Therapy Market For Non-Stem Cell Therapy, 2021 - 2033
4.2.3.2 T-Cell Therapies
4.2.3.2.1 Global Autologous Cell Therapies Market For T-Cell Therapy, 2021 - 2033
4.2.4.2.2 CAR-T Cell Therapy
4.2.4.2.2.1 Global Autologous Cell Therapy Market For CAR-T Cell Therapy, 2021 - 2033
4.2.4.2.3 T-Cell Receptor (TCR)
4.2.4.2.3.1 Global Autologous Cell Therapy Market For T-Cell Receptor (TCR), 2021 - 2033
4.2.3.3 Others
4.2.3.3.1 Global Autologous Cell Therapies Market For Other Autologous Non-Stem Cell Therapies, 2021 - 2033
Chapter 5 Cell Therapy Market Categorization: Therapeutic Area Estimates & Trend Analysis
5.1 Cell Therapy Market: Therapeutic Area Movement Analysis
5.2 Oncology
5.2.1 Global Cell Therapy Market For Oncology Therapies, 2021 - 2033
5.3 Cardiovascular Disease (CVD)
5.3.1 Global Cell Therapy Market For Cardiovascular Disease (CVD) Therapies, 2021 - 2033
5.4 Musculoskeletal Disorders
5.4.1 Global Cell Therapy Market For Musculoskeletal Disorders Therapies, 2021 - 2033
5.5 Dermatology
5.5.1 Global Cell Therapy Market For Dermatology Therapies, 2021 - 2033
5.6 Others
5.6.1 Global Cell Therapy Market For Other Therapies, 2021 - 2033
Chapter 6 Cell Therapy Market Categorization: Regional Estimates & Trend Analysis
6.1 North America
6.1.1 North America Cell Therapy Market Estimates And Forecasts, 2021 - 2033
6.1.2 U.S.
6.1.2.1 Key Country Dynamics
6.1.2.2 Target Disease Prevalence
6.1.2.3 Competitive Scenario
6.1.2.4 Regulatory Framework
6.1.2.6 U.S. Cell Therapy Market Estimates And Forecasts, 2021 - 2033
6.1.3 Canada
6.1.3.1 Key Country Dynamics
6.1.3.2 Target Disease Prevalence
6.1.3.3 Competitive Scenario
6.1.3.4 Regulatory Framework
6.1.3.6 Canada Cell Therapy Market Estimates And Forecasts, 2021 - 2033
6.2 Europe
6.2.1 Europe Cell Therapy Market Estimates And Forecasts, 2021 - 2033
6.2.2 Germany
6.2.2.1 Key Country Dynamics
6.2.2.2 Target Disease Prevalence
6.2.2.3 Competitive Scenario
6.2.2.4 Regulatory Framework
6.2.2.6 Germany Cell Therapy Market Estimates And Forecasts, 2021 - 2033
6.2.3 UK
6.2.3.1 Key Country Dynamics
6.2.3.2 Target Disease Prevalence
6.2.3.3 Competitive Scenario
6.2.3.4 Regulatory Framework
6.2.3.6 UK Cell Therapy Market Estimates And Forecasts, 2021 - 2033
6.2.4 Switzerland
6.2.4.1 Key Country Dynamics
6.2.4.2 Target Disease Prevalence
6.2.4.3 Competitive Scenario
6.2.4.4 Regulatory Framework
6.2.4.6 Switzerland Cell Therapy Market Estimates And Forecasts, 2021 - 2033
6.3 Asia Pacific
6.3.1 Asia Pacific Cell Therapy Market Estimates And Forecasts, 2021 - 2033
6.3.2 Japan
6.3.2.1 Target Disease Prevalence
6.3.2.2 Competitive Scenario
6.3.2.3 Regulatory Framework
6.3.2.5 Japan Cell Therapy Market Estimates And Forecasts, 2021 - 2033
6.3.3 China
6.3.3.1 Target Disease Prevalence
6.3.3.2 Competitive Scenario
6.3.3.3 Regulatory Framework
6.3.3.5 China Cell Therapy Market Estimates And Forecasts, 2021 - 2033
6.3.4 India
6.3.4.1 Target Disease Prevalence
6.3.4.2 Competitive Scenario
6.3.4.3 Regulatory Framework
6.3.4.5 India Cell Therapy Market Estimates And Forecasts, 2021 - 2033
6.3.5 South Korea
6.3.5.1 Target Disease Prevalence
6.3.5.2 Competitive Scenario
6.3.5.3 Regulatory Framework
6.3.5.5 South Korea Cell Therapy Market Estimates And Forecasts, 2021 - 2033
6.4 Rest Of The World
6.4.1 Rest Of The World Cell Therapy Market Estimates And Forecasts, 2021 - 2033
Chapter 7 Competitive Landscape
7.1 Company Categorization
7.2 Strategy Mapping
7.3 Company Market Position Analysis, 2024
7.4 Company Profiles/Listing
7.4.1 Novartis AG
7.4.1.1 Company Overview
7.4.1.4 Financial Performance
7.4.1.3 Product Benchmarking
7.4.1.4 Strategic Initiatives
7.4.2 Gilead Sciences, Inc.
7.4.2.1 Company Overview
7.4.2.2 Financial Performance
7.4.2.3 Product Benchmarking
7.4.2.4 Strategic Initiatives
7.4.3 Bristol-Myers Squibb Company
7.4.3.1 Company Overview
7.4.3.2 Financial Performance
7.4.3.3 Product Benchmarking
7.4.3.4 Strategic Initiatives
7.4.4 Johnson & Johnson Services, Inc
7.4.4.1 Company Overview
7.4.4.2 Financial Performance
7.4.4.3 Product Benchmarking
7.4.4.4 Strategic Initiatives
7.4.5 JCR Pharmaceuticals Co., Ltd.
7.4.5.1 Company Overview
7.4.5.2 Financial Performance
7.4.5.3 Product Benchmarking
7.4.5.4 Strategic Initiatives
7.4.6 JW Therapeutics
7.4.6.1 Company Overview
7.4.6.2 Financial Performance
7.4.6.3 Product Benchmarking
7.4.6.4 Strategic Initiatives
7.4.7 Atara Biotherapeutics
7.4.7.1 Company Overview
7.4.7.2 Financial Performance
7.4.7.3 Product Benchmarking
7.4.7.4 Strategic Initiatives
7.4.8 MEDIPOST
7.4.8.1 Company Overview
7.4.8.2 Financial Performance
7.4.8.3 Product Benchmarking
7.4.8.4 Strategic Initiatives
7.4.9 Anterogen Co., Ltd.
7.4.9.1 Company Overview
7.4.9.2 Financial Performance
7.4.9.3 Product Benchmarking
7.4.9.4 Strategic Initiatives
7.4.10 S. BIOMEDICS
7.4.10.1 Company Overview
7.4.10.2 Financial Performance
7.4.10.3 Product Benchmarking
7.4.10.4 Strategic Initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers